Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...
Vous n'êtes pas connecté
VANCOUVER, British Columbia, Sept. 03, 2024 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today reported, as required by the Nasdaq Stock Market Rule 5635(c) (the “Nasdaq Rule”), an equity inducement award to Ms. Leone […]
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...
Presentations to highlight progress in development of IND candidates ZW220 and ZW251 based on Zymeworks’ proprietary antibody-drug conjugate...
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
Stealth BioTherapeutics Inc., a clinical─stage biotechnology company focused on the discovery, development and commercialization of novel therapies...
VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...
VANCOUVER, British Columbia & NEW YORK — Integrated Nanotherapeutics (INT), a biotechnology company developing innovative treatments for...
NEW YORK, Sept. 4, 2024. Immunic, Inc., a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com SAN...